États-Unis · Plateformes & données · MarketBeat

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

Publié par MarketBeat · États-Unis il y a 1 h

vTv Therapeutics (NASDAQ:VTVT) used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

À lire aussi

Oracle Calls Force Majeure Already?

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

NextDC shares plunge 42% to a near nine-year low after outlook cut

Fifth Third Bancorp (FITB) Posted Strong Q3 2026 Earnings After Its Largest Conversion

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

Partager

À lire aussi

Oracle Calls Force Majeure Already?

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

NextDC shares plunge 42% to a near nine-year low after outlook cut

Fifth Third Bancorp (FITB) Posted Strong Q3 2026 Earnings After Its Largest Conversion

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China